When was T-CURX founded?

T-CURX was founded in 2016 and raised its 1st funding round 2 years after it was founded.

Where is T-CURX located?

T-CURX is headquartered in Wurzburg, Germany. It is registered at Friedrich-Bergius-Ring 15, 97076 Würzburg.

How many employees does T-CURX have?

As of Sep 30, 2026, the latest employee count at T-CURX is 22.

Is T-CURX a funded company?

T-CURX is a funded company, having raised a total of $20.8M across 2 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jan 01, 2018.

When was the latest funding round of T-CURX?

T-CURX's latest funding was a $***** Series A round on Dec 17, 2025, with participation from 3 investors.

Where does T-CURX rank among its competitors?

T-CURX ranks 455th amongst 3422 active competitors, of which 1151 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of T-CURX?

T-CURX's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

T-CURX - 2026 Company Profile, Team, Funding & Competitors

Company Details

T-CURX is developing immune-based cancer treatments with T-cells. They are developing new generation UltraModularCAR T cells (transformative, chemotherapy-free treatment) for treating leukemia, lymphoma, breast cancer, and lung cancer. It's in phase I/II a clinical trial for safety and efficacy evaluation.

Website: t-curx.com
Email ID: *****@t-curx.com
Phone Number: +49 **********
Registered Address: Friedrich-Bergius-Ring 15, 97076 Würzburg

Key Metrics

Founded Year

2016

Location

Wurzburg, Germany

Stage

Series A

Total Funding

$20.8M in 2 rounds

Latest Funding Round

Series A, Dec 17, 2025, $*****

Investors

BioMedPartners & 4 more

Ranked

455^th among 3422 active competitors

Employee Count

22 as on Sep 30, 2026

Investment & Acquisitions

Pantherna Therapeutics

Similar Companies

Jazz Pharmaceuticals & 3174 more

View T-CURX's full profile

T-CURX is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
T-curx Gmbh CIN: D4708_HRB13602 , Germany, Active	Mar 06, 2017	-	-

T-CURX has raised a total funding of $20.8M over 2 rounds. Its first funding round was on Jan 01, 2018. Its latest funding round was a Series A round on Dec 17, 2025 for $*****. 3 investors participated in its latest round. T-CURX has 5 institutional investors.

Here is the list of recent funding rounds of T-CURX:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 17, 2025	3354832	Series A	3500735	8849229	6214751	3483112
Jan 01, 2018	3557867	Grant (prize money)	7385296	3099420	6151037	Europa

Access funding benchmarks and valuations. Sign up today!

View details of T-CURX's funding rounds and investors

The founders of T-CURX is Christian Sollner.

Here are the details of T-CURX's key team members:

Christian Sollner: Founder of T-CURX.
Contact Info: 1 email address

View details of T-CURX's Founder profiles and Board Members

T-CURX's employee count trend

T-CURX has 22 employees as of Sep 26. Here is T-CURX's employee count trend over the years:

Uncover T-CURX's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of T-CURX include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of T-CURX, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
455th	T-CURX 2016, Wurzburg (Germany), Series A	Developer of immune-based cancer treatments with T-cells	$20.8M	Bayern Kapital, BioMedPartners & 3 others	54/100